Immunocompatibility of Bacteriophages as Nanomedicines

Bacteriophage-based medical research provides the opportunity to develop targeted nanomedicines with heightened efficiency and safety profiles. Filamentous phages also can and have been formulated as targeted drug-delivery nanomedicines, and phage may also serve as promising alternatives/complements...

Full description

Saved in:
Bibliographic Details
Main Authors: Tranum Kaur, Nafiseh Nafissi, Olla Wasfi, Katlyn Sheldon, Shawn Wettig, Roderick Slavcev
Format: Article
Language:English
Published: Wiley 2012-01-01
Series:Journal of Nanotechnology
Online Access:http://dx.doi.org/10.1155/2012/247427
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832567236795039744
author Tranum Kaur
Nafiseh Nafissi
Olla Wasfi
Katlyn Sheldon
Shawn Wettig
Roderick Slavcev
author_facet Tranum Kaur
Nafiseh Nafissi
Olla Wasfi
Katlyn Sheldon
Shawn Wettig
Roderick Slavcev
author_sort Tranum Kaur
collection DOAJ
description Bacteriophage-based medical research provides the opportunity to develop targeted nanomedicines with heightened efficiency and safety profiles. Filamentous phages also can and have been formulated as targeted drug-delivery nanomedicines, and phage may also serve as promising alternatives/complements to antibiotics. Over the past decade the use of phage for both the prophylaxis and the treatment of bacterial infection, has gained special significance in view of a dramatic rise in the prevalence of antibiotic resistance bacterial strains. Two potential medical applications of phages are the treatment of bacterial infections and their use as immunizing agents in diagnosis and monitoring patients with immunodeficiencies. Recently, phages have been employed as gene-delivery vectors (phage nanomedicine), for nearly half a century as tools in genetic research, for about two decades as tools for the discovery of specific target-binding proteins and peptides, and for almost a decade as tools for vaccine development. As phage applications to human therapeutic development grow at an exponential rate, it will become essential to evaluate host immune responses to initial and repetitive challenges by therapeutic phage in order to develop phage therapies that offer suitable utility. This paper examines and discusses phage nanomedicine applications and the immunomodulatory effects of bacteriophage exposure and treatment modalities.
format Article
id doaj-art-7798cb39ef1445e8ad92b2c20d71cbec
institution Kabale University
issn 1687-9503
1687-9511
language English
publishDate 2012-01-01
publisher Wiley
record_format Article
series Journal of Nanotechnology
spelling doaj-art-7798cb39ef1445e8ad92b2c20d71cbec2025-02-03T01:02:03ZengWileyJournal of Nanotechnology1687-95031687-95112012-01-01201210.1155/2012/247427247427Immunocompatibility of Bacteriophages as NanomedicinesTranum Kaur0Nafiseh Nafissi1Olla Wasfi2Katlyn Sheldon3Shawn Wettig4Roderick Slavcev5School of Pharmacy, University of Waterloo, Health Sciences Campus, 10 Victoria Street South, Kitchener, ON, N2L 3C4, CanadaSchool of Pharmacy, University of Waterloo, Health Sciences Campus, 10 Victoria Street South, Kitchener, ON, N2L 3C4, CanadaSchool of Pharmacy, University of Waterloo, Health Sciences Campus, 10 Victoria Street South, Kitchener, ON, N2L 3C4, CanadaSchool of Pharmacy, University of Waterloo, Health Sciences Campus, 10 Victoria Street South, Kitchener, ON, N2L 3C4, CanadaSchool of Pharmacy, University of Waterloo, Health Sciences Campus, 10 Victoria Street South, Kitchener, ON, N2L 3C4, CanadaSchool of Pharmacy, University of Waterloo, Health Sciences Campus, 10 Victoria Street South, Kitchener, ON, N2L 3C4, CanadaBacteriophage-based medical research provides the opportunity to develop targeted nanomedicines with heightened efficiency and safety profiles. Filamentous phages also can and have been formulated as targeted drug-delivery nanomedicines, and phage may also serve as promising alternatives/complements to antibiotics. Over the past decade the use of phage for both the prophylaxis and the treatment of bacterial infection, has gained special significance in view of a dramatic rise in the prevalence of antibiotic resistance bacterial strains. Two potential medical applications of phages are the treatment of bacterial infections and their use as immunizing agents in diagnosis and monitoring patients with immunodeficiencies. Recently, phages have been employed as gene-delivery vectors (phage nanomedicine), for nearly half a century as tools in genetic research, for about two decades as tools for the discovery of specific target-binding proteins and peptides, and for almost a decade as tools for vaccine development. As phage applications to human therapeutic development grow at an exponential rate, it will become essential to evaluate host immune responses to initial and repetitive challenges by therapeutic phage in order to develop phage therapies that offer suitable utility. This paper examines and discusses phage nanomedicine applications and the immunomodulatory effects of bacteriophage exposure and treatment modalities.http://dx.doi.org/10.1155/2012/247427
spellingShingle Tranum Kaur
Nafiseh Nafissi
Olla Wasfi
Katlyn Sheldon
Shawn Wettig
Roderick Slavcev
Immunocompatibility of Bacteriophages as Nanomedicines
Journal of Nanotechnology
title Immunocompatibility of Bacteriophages as Nanomedicines
title_full Immunocompatibility of Bacteriophages as Nanomedicines
title_fullStr Immunocompatibility of Bacteriophages as Nanomedicines
title_full_unstemmed Immunocompatibility of Bacteriophages as Nanomedicines
title_short Immunocompatibility of Bacteriophages as Nanomedicines
title_sort immunocompatibility of bacteriophages as nanomedicines
url http://dx.doi.org/10.1155/2012/247427
work_keys_str_mv AT tranumkaur immunocompatibilityofbacteriophagesasnanomedicines
AT nafisehnafissi immunocompatibilityofbacteriophagesasnanomedicines
AT ollawasfi immunocompatibilityofbacteriophagesasnanomedicines
AT katlynsheldon immunocompatibilityofbacteriophagesasnanomedicines
AT shawnwettig immunocompatibilityofbacteriophagesasnanomedicines
AT roderickslavcev immunocompatibilityofbacteriophagesasnanomedicines